Cytosorbents Corp.'s march to get its Cytosorb technology available to the U.S. market gained significant momentum last week, after the FDA approved the company's IDE trial. REFRESH 2 is a randomized, controlled, multicenter, clinical trial designed to evaluate intraoperative Cytosorb use as a therapy to reduce acute kidney injury (AKI), as measured by Kidney Disease Improving Global Outcomes criteria, following complex cardiac surgery.